Australia's Imugene climbs on FDA clearance for clinical study

Imugene

19/05/2023 02:01

** Shares of clinical-stage oncology co Imugene Ltd  IMU.AX 
rise as much as 13% to A$0.130, their highest since May 2
    ** IMU stock is top gainer in benchmark ASX 200 index
 .AXJO 
    ** Co receives U.S. Food and Drug Administration (FDA)
Investigational New Drug (IND) clearance to start a Phase 1
clinical study for onCARlytics 
    ** Says the onCARlytics study is significant for clinicians
treating patients with solid tumour cancers
    ** Adds the FDA clearance for IND allows co to start patient
recruitment and dosing
    ** As of last close, stock down 20.7% this year

 (Reporting by Himanshi Akhand in Bengaluru)
 ((Himanshi.Akhand@thomsonreuters.com;))